Fluvoxamine versus amitriptyline in the treatment of fibromyalgia [Fibromyalji tedavisinde amitriptilin ve fluvoksaminin karsilastirilmasi]

Basit Öğe Kaydı
dc.contributor.authorErhan E.
dc.contributor.authorUyar M.
dc.contributor.authorTuran S.
dc.contributor.authorYegul I.
dc.contributor.authorTuglular I.
dc.contributor.authorGokce Doering B.
dc.contributor.authorKose T.
dc.date.accessioned2019-10-27T00:26:19Z
dc.date.available2019-10-27T00:26:19Z
dc.date.issued2000
dc.departmentEge Üniversitesien_US
dc.description.abstractIn this study, fluvoxamine, a relatively new selected serotonin reuptake inhibitor, was compared with amitriptyline in a double-blind, crossover study in 15 hospital outpatients suffering from fibromyalgia syndrome. The study was approved by the Ethics Committee of Ege University Hospital and informed consent was obtained from each patient. Exclusion criteria for the investigation were presence of psychiatric diagnosis, rheumatic disease and other systemic co-existing disease. Flowing a 2 week wash-out period for analgesic and/or adjuvan drugs, patients randomly received 25 mg amitriptyline or 50 mg fluvoxamine for a period of 4-weeks. After a 2-week wash-out pedod, patients were re-evaluated before receiving the second drug for another 4 weeks. Assesment of efficacy was made on entry and at 2 week intervals for each drug using visual analog scale (VAS) scores, number of tender points, presence and degree of minor criteria symptoms. Analysis of variance and Wilcoxon matched pairs were used for the statistical comparison of the data. At the end of the trial, there was a significant reduction in VAS scores, number of tender points as well as the severity of the minor criteria symptoms. Overall there were no significant differences in terms of efficacy between the two drugs except anxiety. Anxiety scores in fiuvoxamine group were significantly lower than the amitriptyline group. It was concluded that fiuvoxamine in an effective, well-tolerated alternative to amitriptyline in the treatment of fibromyalgia syndrome.en_US
dc.identifier.endpage36en_US
dc.identifier.issn1300-0012
dc.identifier.issn1300-0012en_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage32en_US
dc.identifier.urihttps://hdl.handle.net/11454/23378
dc.identifier.volume12en_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.relation.ispartofAgrien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAmitriptylineen_US
dc.subjectFibromyalgia syndromeen_US
dc.subjectFluvoxamineen_US
dc.titleFluvoxamine versus amitriptyline in the treatment of fibromyalgia [Fibromyalji tedavisinde amitriptilin ve fluvoksaminin karsilastirilmasi]en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu